Financial reports
ARS
2023 FY
Annual report to shareholders
11 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
21 Mar 24
8-K
Dianthus Therapeutics Announces $230 Million Private Placement
22 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Other Events
21 Dec 23
8-K
Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results
9 Nov 23
8-K
Changes in Registrant's Certifying Accountant
25 Oct 23
8-K/A
Results of Operations and Financial Condition
20 Sep 23
8-K
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
12 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
8 Sep 23
8-K
Departure of Directors or Certain Officers
19 May 23
Registration and prospectus
S-8
Registration of securities for employees
21 Mar 24
S-1/A
IPO registration (amended)
21 Mar 24
S-1/A
IPO registration (amended)
7 Feb 24
S-1/A
IPO registration (amended)
21 Dec 23
S-8
Registration of securities for employees
4 Oct 23
S-3
Shelf registration
4 Oct 23
425
Business combination disclosure
31 Aug 23
424B3
Prospectus supplement
1 Aug 23
Proxies
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Apr 19
DEF 14A
Definitive proxy
25 Apr 19
Other
EFFECT
Notice of effectiveness
28 Mar 24
EFFECT
Notice of effectiveness
2 Aug 23
CORRESP
Correspondence with SEC
31 Jul 23
CORRESP
Correspondence with SEC
17 Jul 23
UPLOAD
Letter from SEC
6 Jul 23
CORRESP
Correspondence with SEC
22 Jun 23
UPLOAD
Letter from SEC
13 Jun 23
EFFECT
Notice of effectiveness
15 Aug 22
CORRESP
Correspondence with SEC
10 Aug 22
UPLOAD
Letter from SEC
9 Aug 22
Ownership
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
4
Tomas Kiselak
1 Apr 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
5AM Partners VII, LLC
14 Feb 24
SC 13G/A
Third Rock Ventures IV, L.P.
14 Feb 24
SC 13G/A
GV 2016, L.P.
9 Feb 24
SC 13G
BCLS Fund III Investments, LP
2 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
2 Feb 24
SC 13D
Avidity Partners Management LP
31 Jan 24
4
EDWARD CARR
26 Jan 24